Last 102.30
Change Today +3.30 / 3.33%
Volume 6.2M
As of 10:24 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd (BLRX) Snapshot

Open
$103.00
Previous Close
$99.00
Day High
$105.90
Day Low
$101.00
52 Week High
03/4/15 - $105.90
52 Week Low
12/3/14 - $46.80
Market Cap
400.1M
Average Volume 10 Days
2.6M
EPS TTM
$-0.14
Shares Outstanding
391.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD (BLRX)

biolinerx ltd (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

43 Employees
Last Reported Date: 03/17/14
Founded in 2003

biolinerx ltd (BLRX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biolinerx ltd (BLRX) Key Developments

BioLineRx, Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 09:30 AM

BioLineRx, Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-19-2015 09:30 AM. Venue: Dan Panorama Hotel, Charles Clore Park, Tel Aviv 68012, Israel. Speakers: David Malek, Vice President of Business Development.

BioLineRx, Ltd. Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040)

BioLineRx, Ltd. announced that patient enrollment has been completed in Bellerophon's PRESERVATION I pivotal CE Mark registration trial of BL-1040, currently named Bioabsorbable Cardiac Matrix (BCM), a novel resorbable polymer solution for the prevention of cardiac remodeling following an acute myocardial infarction (AMI). The PRESERVATION I CE Mark registration trial is a double-blind, placebo-controlled study aimed at evaluating the safety and effectiveness of BL-1040 in the prevention of ventricular remodeling and congestive heart failure when administered following AMI. Three hundred and three AMI patients were enrolled and treated at almost 90 sites worldwide, 16 of which are in the U.S. The study, which includes a six-month follow-up period, is anticipated to be completed in mid-2015.

BioLineRx, Ltd. Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment

BioLineRx, Ltd. announced that it has completed the dose escalation stage of a Phase 1 trial for its novel oncology platform, BL-8040, as a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. All healthy volunteers completed the treatment phase and results are expected during the first quarter of 2015. BL-8040 is being developed along multiple tracks for the treatment of hematological malignancies and other hematological indications, with multiple clinical milestones expected in 2015. In parallel, BL-8040 is also undergoing a Phase 2 study for treating relapsed and refractory acute myeloid leukemia patients, the results of which are expected in the second half 2015. The Phase 1 study consists of two parts. The first part is a randomized, double-blind, placebo-controlled dose escalation study exploring the safety and tolerability of escalating repeated doses of BL-8040 in healthy volunteers. Secondary objectives include assessment of the efficacy of BL-8040 in mobilizing stem cells as a stand-alone therapy, as well as determining the pharmacodynamic and pharmacokinetic profile of the drug. This part was performed in three cohorts, with eight healthy volunteers in each cohort. Following analysis of the data, the optimal safe and efficacious dose of BL-8040 will be selected to be used as a stand-alone therapy in the second part of the study. The second part of the study is an open-label study designed to assess BL-8040's stem cell mobilization capacity, as well as the yield of cells collected by apheresis. Secondary endpoints of the study include evaluation of the viability and biological activity of cells mobilized by BL-8040 and collected by apheresis. This part will be performed in a single cohort of eight healthy volunteers who will receive the selected dose regimen of BL-8040 based on the data from the first part of the study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:IT 103.30 +4.30

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.